Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis
Background/Aims: Endocannabinoids include anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG). Endocannabinoid‐related molecules like oleoyl‐ethanolamine (OEA) and palmitoyl‐ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental...
Gespeichert in:
| Veröffentlicht in: | Liver international 2010-07, Vol.30 (6), p.816-825 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 825 |
|---|---|
| container_issue | 6 |
| container_start_page | 816 |
| container_title | Liver international |
| container_volume | 30 |
| creator | Caraceni, Paolo Viola, Antonella Piscitelli, Fabiana Giannone, Ferdinando Berzigotti, Annalisa Cescon, Matteo Domenicali, Marco Petrosino, Stefania Giampalma, Emanuela Riili, Anna Grazi, Gianluca Golfieri, Rita Zoli, Marco Bernardi, Mauro Di Marzo, Vincenzo |
| description | Background/Aims: Endocannabinoids include anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG). Endocannabinoid‐related molecules like oleoyl‐ethanolamine (OEA) and palmitoyl‐ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental cirrhosis, but data on the endocannabinoid system in human cirrhosis are lacking. Thus, we aimed to assess whether circulating and hepatic endocannabinoids are upregulated in cirrhotic patients and whether their levels correlate with systemic haemodynamics and liver function.
Methods: The endocannabinoid levels were measured in peripheral and hepatic veins and liver tissue by isotope‐dilution liquid chromatography‐atmospheric pressure chemical ionization‐mass spectrometry. Systemic haemodynamics were assessed by the transthoracic electrical bioimpedance technique. Portal pressure was evaluated by hepatic venous pressure gradient.
Results: Circulating AEA and, to a greater extent, PEA and OEA were significantly higher in cirrhotic patients than in controls. PEA and OEA were also increased in the cirrhotic liver tissue. AEA, OEA and PEA levels were significantly higher in peripheral than in the hepatic veins of cirrhotic patients, while the opposite occurred for 2‐AG. Finally, circulating AEA, OEA and PEA correlated with parameters of liver function, such as serum bilirubin and international normalized ratio. No correlations were found with systemic haemodynamics.
Conclusions:
The endocannabinoid system is upregulated in human cirrhosis. Peripheral AEA is increased in patients with a high model of end‐stage liver disease score and may reflect the extent of liver dysfunction. In contrast, the 2‐AG levels, the other major endocannabinoid, are not affected by cirrhosis. The upregulation of the endocannabinoid‐related molecules, OEA and PEA, is even greater than that of AEA, prompting pharmacological studies on these compounds. |
| doi_str_mv | 10.1111/j.1478-3231.2009.02137.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733975570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733975570</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3577-dc81daad2a33e8b675452e353e5c1428f02af00e9b7b84702bb68833286487d43</originalsourceid><addsrcrecordid>eNpdkc1OwzAQhC0EglJ4BeQbpwT_xLFz4IAqKBUVSKjA0XLiLXVJnRKnanl7ElqKhC9ee-bbwwxCmJKYtudqHtNEqogzTmNGSBYTRrmMNweotxcO9zPjJ-g0hDkhNMsEPUYnNFMJYYnoITdwdbEqTeP8Ozbe4hks20eBwduqMN6b3PnK2fAj_vuMamhJsHhRldBugYCdxx0Pvgl47ZoZLlxdz6rgwhk6mpoywPnu7qOXu9vJ4D4aPw1Hg5txVHAhZWQLRa0xlhnOQeWpFIlgwAUHUdCEqSlhZkoIZLnMVSIJy_NUKc6ZShMlbcL76HK7d1lXnysIjV64UEBZGg_VKmjJeSaFkKR1Xuycq3wBVi9rtzD1l_5NpzVcbw1rV8LXn05014Ke6y5g3YWtuxb0Twt6o8ej125q-WjLu9DAZs-b-kOnkkuh3x6HOn1m2WTyKPUD_wbAd4sj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733975570</pqid></control><display><type>article</type><title>Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Caraceni, Paolo ; Viola, Antonella ; Piscitelli, Fabiana ; Giannone, Ferdinando ; Berzigotti, Annalisa ; Cescon, Matteo ; Domenicali, Marco ; Petrosino, Stefania ; Giampalma, Emanuela ; Riili, Anna ; Grazi, Gianluca ; Golfieri, Rita ; Zoli, Marco ; Bernardi, Mauro ; Di Marzo, Vincenzo</creator><creatorcontrib>Caraceni, Paolo ; Viola, Antonella ; Piscitelli, Fabiana ; Giannone, Ferdinando ; Berzigotti, Annalisa ; Cescon, Matteo ; Domenicali, Marco ; Petrosino, Stefania ; Giampalma, Emanuela ; Riili, Anna ; Grazi, Gianluca ; Golfieri, Rita ; Zoli, Marco ; Bernardi, Mauro ; Di Marzo, Vincenzo</creatorcontrib><description>Background/Aims: Endocannabinoids include anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG). Endocannabinoid‐related molecules like oleoyl‐ethanolamine (OEA) and palmitoyl‐ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental cirrhosis, but data on the endocannabinoid system in human cirrhosis are lacking. Thus, we aimed to assess whether circulating and hepatic endocannabinoids are upregulated in cirrhotic patients and whether their levels correlate with systemic haemodynamics and liver function.
Methods: The endocannabinoid levels were measured in peripheral and hepatic veins and liver tissue by isotope‐dilution liquid chromatography‐atmospheric pressure chemical ionization‐mass spectrometry. Systemic haemodynamics were assessed by the transthoracic electrical bioimpedance technique. Portal pressure was evaluated by hepatic venous pressure gradient.
Results: Circulating AEA and, to a greater extent, PEA and OEA were significantly higher in cirrhotic patients than in controls. PEA and OEA were also increased in the cirrhotic liver tissue. AEA, OEA and PEA levels were significantly higher in peripheral than in the hepatic veins of cirrhotic patients, while the opposite occurred for 2‐AG. Finally, circulating AEA, OEA and PEA correlated with parameters of liver function, such as serum bilirubin and international normalized ratio. No correlations were found with systemic haemodynamics.
Conclusions:
The endocannabinoid system is upregulated in human cirrhosis. Peripheral AEA is increased in patients with a high model of end‐stage liver disease score and may reflect the extent of liver dysfunction. In contrast, the 2‐AG levels, the other major endocannabinoid, are not affected by cirrhosis. The upregulation of the endocannabinoid‐related molecules, OEA and PEA, is even greater than that of AEA, prompting pharmacological studies on these compounds.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/j.1478-3231.2009.02137.x</identifier><identifier>PMID: 19840245</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Arachidonic Acids - metabolism ; Bilirubin - blood ; Biomarkers - blood ; Cannabinoid Receptor Modulators - blood ; Cannabinoid Receptor Modulators - metabolism ; Case-Control Studies ; Chromatography, Liquid ; cirrhosis ; Electric Impedance ; Endocannabinoids ; Ethanolamines - metabolism ; Female ; Glycerides - metabolism ; Hemodynamics ; Humans ; International Normalized Ratio ; Italy ; Liver - blood supply ; Liver - metabolism ; Liver - physiopathology ; Liver Cirrhosis - blood ; Liver Cirrhosis - metabolism ; Liver Cirrhosis - physiopathology ; liver dysfunction ; Liver Function Tests ; Male ; Mass Spectrometry ; Middle Aged ; Oleic Acids ; Palmitic Acids - metabolism ; Polyunsaturated Alkamides - metabolism ; portal hypertension ; Radioisotope Dilution Technique ; Severity of Illness Index ; systemic haemodynamics ; Up-Regulation</subject><ispartof>Liver international, 2010-07, Vol.30 (6), p.816-825</ispartof><rights>2009 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3577-dc81daad2a33e8b675452e353e5c1428f02af00e9b7b84702bb68833286487d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1478-3231.2009.02137.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1478-3231.2009.02137.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19840245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caraceni, Paolo</creatorcontrib><creatorcontrib>Viola, Antonella</creatorcontrib><creatorcontrib>Piscitelli, Fabiana</creatorcontrib><creatorcontrib>Giannone, Ferdinando</creatorcontrib><creatorcontrib>Berzigotti, Annalisa</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Domenicali, Marco</creatorcontrib><creatorcontrib>Petrosino, Stefania</creatorcontrib><creatorcontrib>Giampalma, Emanuela</creatorcontrib><creatorcontrib>Riili, Anna</creatorcontrib><creatorcontrib>Grazi, Gianluca</creatorcontrib><creatorcontrib>Golfieri, Rita</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Bernardi, Mauro</creatorcontrib><creatorcontrib>Di Marzo, Vincenzo</creatorcontrib><title>Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background/Aims: Endocannabinoids include anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG). Endocannabinoid‐related molecules like oleoyl‐ethanolamine (OEA) and palmitoyl‐ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental cirrhosis, but data on the endocannabinoid system in human cirrhosis are lacking. Thus, we aimed to assess whether circulating and hepatic endocannabinoids are upregulated in cirrhotic patients and whether their levels correlate with systemic haemodynamics and liver function.
Methods: The endocannabinoid levels were measured in peripheral and hepatic veins and liver tissue by isotope‐dilution liquid chromatography‐atmospheric pressure chemical ionization‐mass spectrometry. Systemic haemodynamics were assessed by the transthoracic electrical bioimpedance technique. Portal pressure was evaluated by hepatic venous pressure gradient.
Results: Circulating AEA and, to a greater extent, PEA and OEA were significantly higher in cirrhotic patients than in controls. PEA and OEA were also increased in the cirrhotic liver tissue. AEA, OEA and PEA levels were significantly higher in peripheral than in the hepatic veins of cirrhotic patients, while the opposite occurred for 2‐AG. Finally, circulating AEA, OEA and PEA correlated with parameters of liver function, such as serum bilirubin and international normalized ratio. No correlations were found with systemic haemodynamics.
Conclusions:
The endocannabinoid system is upregulated in human cirrhosis. Peripheral AEA is increased in patients with a high model of end‐stage liver disease score and may reflect the extent of liver dysfunction. In contrast, the 2‐AG levels, the other major endocannabinoid, are not affected by cirrhosis. The upregulation of the endocannabinoid‐related molecules, OEA and PEA, is even greater than that of AEA, prompting pharmacological studies on these compounds.</description><subject>Adult</subject><subject>Arachidonic Acids - metabolism</subject><subject>Bilirubin - blood</subject><subject>Biomarkers - blood</subject><subject>Cannabinoid Receptor Modulators - blood</subject><subject>Cannabinoid Receptor Modulators - metabolism</subject><subject>Case-Control Studies</subject><subject>Chromatography, Liquid</subject><subject>cirrhosis</subject><subject>Electric Impedance</subject><subject>Endocannabinoids</subject><subject>Ethanolamines - metabolism</subject><subject>Female</subject><subject>Glycerides - metabolism</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>International Normalized Ratio</subject><subject>Italy</subject><subject>Liver - blood supply</subject><subject>Liver - metabolism</subject><subject>Liver - physiopathology</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - metabolism</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>liver dysfunction</subject><subject>Liver Function Tests</subject><subject>Male</subject><subject>Mass Spectrometry</subject><subject>Middle Aged</subject><subject>Oleic Acids</subject><subject>Palmitic Acids - metabolism</subject><subject>Polyunsaturated Alkamides - metabolism</subject><subject>portal hypertension</subject><subject>Radioisotope Dilution Technique</subject><subject>Severity of Illness Index</subject><subject>systemic haemodynamics</subject><subject>Up-Regulation</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1OwzAQhC0EglJ4BeQbpwT_xLFz4IAqKBUVSKjA0XLiLXVJnRKnanl7ElqKhC9ee-bbwwxCmJKYtudqHtNEqogzTmNGSBYTRrmMNweotxcO9zPjJ-g0hDkhNMsEPUYnNFMJYYnoITdwdbEqTeP8Ozbe4hks20eBwduqMN6b3PnK2fAj_vuMamhJsHhRldBugYCdxx0Pvgl47ZoZLlxdz6rgwhk6mpoywPnu7qOXu9vJ4D4aPw1Hg5txVHAhZWQLRa0xlhnOQeWpFIlgwAUHUdCEqSlhZkoIZLnMVSIJy_NUKc6ZShMlbcL76HK7d1lXnysIjV64UEBZGg_VKmjJeSaFkKR1Xuycq3wBVi9rtzD1l_5NpzVcbw1rV8LXn05014Ke6y5g3YWtuxb0Twt6o8ej125q-WjLu9DAZs-b-kOnkkuh3x6HOn1m2WTyKPUD_wbAd4sj</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Caraceni, Paolo</creator><creator>Viola, Antonella</creator><creator>Piscitelli, Fabiana</creator><creator>Giannone, Ferdinando</creator><creator>Berzigotti, Annalisa</creator><creator>Cescon, Matteo</creator><creator>Domenicali, Marco</creator><creator>Petrosino, Stefania</creator><creator>Giampalma, Emanuela</creator><creator>Riili, Anna</creator><creator>Grazi, Gianluca</creator><creator>Golfieri, Rita</creator><creator>Zoli, Marco</creator><creator>Bernardi, Mauro</creator><creator>Di Marzo, Vincenzo</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201007</creationdate><title>Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis</title><author>Caraceni, Paolo ; Viola, Antonella ; Piscitelli, Fabiana ; Giannone, Ferdinando ; Berzigotti, Annalisa ; Cescon, Matteo ; Domenicali, Marco ; Petrosino, Stefania ; Giampalma, Emanuela ; Riili, Anna ; Grazi, Gianluca ; Golfieri, Rita ; Zoli, Marco ; Bernardi, Mauro ; Di Marzo, Vincenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3577-dc81daad2a33e8b675452e353e5c1428f02af00e9b7b84702bb68833286487d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Arachidonic Acids - metabolism</topic><topic>Bilirubin - blood</topic><topic>Biomarkers - blood</topic><topic>Cannabinoid Receptor Modulators - blood</topic><topic>Cannabinoid Receptor Modulators - metabolism</topic><topic>Case-Control Studies</topic><topic>Chromatography, Liquid</topic><topic>cirrhosis</topic><topic>Electric Impedance</topic><topic>Endocannabinoids</topic><topic>Ethanolamines - metabolism</topic><topic>Female</topic><topic>Glycerides - metabolism</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>International Normalized Ratio</topic><topic>Italy</topic><topic>Liver - blood supply</topic><topic>Liver - metabolism</topic><topic>Liver - physiopathology</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - metabolism</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>liver dysfunction</topic><topic>Liver Function Tests</topic><topic>Male</topic><topic>Mass Spectrometry</topic><topic>Middle Aged</topic><topic>Oleic Acids</topic><topic>Palmitic Acids - metabolism</topic><topic>Polyunsaturated Alkamides - metabolism</topic><topic>portal hypertension</topic><topic>Radioisotope Dilution Technique</topic><topic>Severity of Illness Index</topic><topic>systemic haemodynamics</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caraceni, Paolo</creatorcontrib><creatorcontrib>Viola, Antonella</creatorcontrib><creatorcontrib>Piscitelli, Fabiana</creatorcontrib><creatorcontrib>Giannone, Ferdinando</creatorcontrib><creatorcontrib>Berzigotti, Annalisa</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Domenicali, Marco</creatorcontrib><creatorcontrib>Petrosino, Stefania</creatorcontrib><creatorcontrib>Giampalma, Emanuela</creatorcontrib><creatorcontrib>Riili, Anna</creatorcontrib><creatorcontrib>Grazi, Gianluca</creatorcontrib><creatorcontrib>Golfieri, Rita</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Bernardi, Mauro</creatorcontrib><creatorcontrib>Di Marzo, Vincenzo</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caraceni, Paolo</au><au>Viola, Antonella</au><au>Piscitelli, Fabiana</au><au>Giannone, Ferdinando</au><au>Berzigotti, Annalisa</au><au>Cescon, Matteo</au><au>Domenicali, Marco</au><au>Petrosino, Stefania</au><au>Giampalma, Emanuela</au><au>Riili, Anna</au><au>Grazi, Gianluca</au><au>Golfieri, Rita</au><au>Zoli, Marco</au><au>Bernardi, Mauro</au><au>Di Marzo, Vincenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2010-07</date><risdate>2010</risdate><volume>30</volume><issue>6</issue><spage>816</spage><epage>825</epage><pages>816-825</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background/Aims: Endocannabinoids include anandamide (AEA) and 2‐arachidonoylglycerol (2‐AG). Endocannabinoid‐related molecules like oleoyl‐ethanolamine (OEA) and palmitoyl‐ethanolamine (PEA) have also been identified. AEA contributes to the pathogenesis of cardiovascular alterations in experimental cirrhosis, but data on the endocannabinoid system in human cirrhosis are lacking. Thus, we aimed to assess whether circulating and hepatic endocannabinoids are upregulated in cirrhotic patients and whether their levels correlate with systemic haemodynamics and liver function.
Methods: The endocannabinoid levels were measured in peripheral and hepatic veins and liver tissue by isotope‐dilution liquid chromatography‐atmospheric pressure chemical ionization‐mass spectrometry. Systemic haemodynamics were assessed by the transthoracic electrical bioimpedance technique. Portal pressure was evaluated by hepatic venous pressure gradient.
Results: Circulating AEA and, to a greater extent, PEA and OEA were significantly higher in cirrhotic patients than in controls. PEA and OEA were also increased in the cirrhotic liver tissue. AEA, OEA and PEA levels were significantly higher in peripheral than in the hepatic veins of cirrhotic patients, while the opposite occurred for 2‐AG. Finally, circulating AEA, OEA and PEA correlated with parameters of liver function, such as serum bilirubin and international normalized ratio. No correlations were found with systemic haemodynamics.
Conclusions:
The endocannabinoid system is upregulated in human cirrhosis. Peripheral AEA is increased in patients with a high model of end‐stage liver disease score and may reflect the extent of liver dysfunction. In contrast, the 2‐AG levels, the other major endocannabinoid, are not affected by cirrhosis. The upregulation of the endocannabinoid‐related molecules, OEA and PEA, is even greater than that of AEA, prompting pharmacological studies on these compounds.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19840245</pmid><doi>10.1111/j.1478-3231.2009.02137.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2010-07, Vol.30 (6), p.816-825 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733975570 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Arachidonic Acids - metabolism Bilirubin - blood Biomarkers - blood Cannabinoid Receptor Modulators - blood Cannabinoid Receptor Modulators - metabolism Case-Control Studies Chromatography, Liquid cirrhosis Electric Impedance Endocannabinoids Ethanolamines - metabolism Female Glycerides - metabolism Hemodynamics Humans International Normalized Ratio Italy Liver - blood supply Liver - metabolism Liver - physiopathology Liver Cirrhosis - blood Liver Cirrhosis - metabolism Liver Cirrhosis - physiopathology liver dysfunction Liver Function Tests Male Mass Spectrometry Middle Aged Oleic Acids Palmitic Acids - metabolism Polyunsaturated Alkamides - metabolism portal hypertension Radioisotope Dilution Technique Severity of Illness Index systemic haemodynamics Up-Regulation |
| title | Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T19%3A52%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20and%20hepatic%20endocannabinoids%20and%20endocannabinoid-related%20molecules%20in%20patients%20with%20cirrhosis&rft.jtitle=Liver%20international&rft.au=Caraceni,%20Paolo&rft.date=2010-07&rft.volume=30&rft.issue=6&rft.spage=816&rft.epage=825&rft.pages=816-825&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2009.02137.x&rft_dat=%3Cproquest_pubme%3E733975570%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733975570&rft_id=info:pmid/19840245&rfr_iscdi=true |